JP2019510812A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510812A5 JP2019510812A5 JP2018563747A JP2018563747A JP2019510812A5 JP 2019510812 A5 JP2019510812 A5 JP 2019510812A5 JP 2018563747 A JP2018563747 A JP 2018563747A JP 2018563747 A JP2018563747 A JP 2018563747A JP 2019510812 A5 JP2019510812 A5 JP 2019510812A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- antibody
- polypeptide
- bdm
- molecule according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 101150099985 bdm gene Proteins 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022078237A JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
| JP2023219531A JP7857274B2 (ja) | 2016-02-26 | 2023-12-26 | 多重特異性分子 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016900708A AU2016900708A0 (en) | 2016-02-26 | Multi-specific molecules 1 | |
| AU2016900709A AU2016900709A0 (en) | 2016-02-26 | Multi-specific molecules 2 | |
| AU2016900709 | 2016-02-26 | ||
| AU2016900708 | 2016-02-26 | ||
| PCT/AU2017/050168 WO2017143406A1 (en) | 2016-02-26 | 2017-02-27 | Multi-specific molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078237A Division JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510812A JP2019510812A (ja) | 2019-04-18 |
| JP2019510812A5 true JP2019510812A5 (enExample) | 2020-04-09 |
| JP7536424B2 JP7536424B2 (ja) | 2024-08-20 |
Family
ID=59685848
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563747A Active JP7536424B2 (ja) | 2016-02-26 | 2017-02-27 | 多重特異性分子 |
| JP2022078237A Pending JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
| JP2023219531A Active JP7857274B2 (ja) | 2016-02-26 | 2023-12-26 | 多重特異性分子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022078237A Pending JP2022105574A (ja) | 2016-02-26 | 2022-05-11 | 多重特異性分子 |
| JP2023219531A Active JP7857274B2 (ja) | 2016-02-26 | 2023-12-26 | 多重特異性分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20190338013A1 (enExample) |
| EP (1) | EP3419667A4 (enExample) |
| JP (3) | JP7536424B2 (enExample) |
| CN (1) | CN109310766A (enExample) |
| AU (2) | AU2017222700B2 (enExample) |
| TW (1) | TW201734037A (enExample) |
| WO (1) | WO2017143406A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017222700B2 (en) * | 2016-02-26 | 2018-09-27 | Imunexus Therapeutics Limited | Multi-specific molecules |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| IL270743B2 (en) | 2017-05-19 | 2024-09-01 | Wuxi Biologics Shanghai Co Ltd | Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof |
| KR20210029298A (ko) * | 2017-08-16 | 2021-03-15 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질 |
| SG11202004158QA (en) | 2017-12-28 | 2020-06-29 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies and variants thereof against tigit |
| CN111836832A (zh) * | 2018-01-08 | 2020-10-27 | 南京传奇生物科技有限公司 | 多特异性抗原结合蛋白及其使用方法 |
| CA3084518A1 (en) | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| BR112021012631A2 (pt) | 2018-12-26 | 2021-12-14 | Xilio Dev Inc | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
| US20230002450A1 (en) * | 2019-02-18 | 2023-01-05 | Courier Therapeutics, Inc. | Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner |
| WO2020198353A1 (en) * | 2019-03-26 | 2020-10-01 | Forty Seven, Inc. | Multispecific agents for treatment of cancer |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| WO2021147857A1 (en) * | 2020-01-20 | 2021-07-29 | Wuxi Biologics (Shanghai) Co., Ltd | A novel wash buffer solution for affinity chromatography |
| EP3904378A1 (en) * | 2020-04-29 | 2021-11-03 | Hober Biotech AB | Bispecific protein |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| WO2022081529A1 (en) * | 2020-10-12 | 2022-04-21 | Greffex, Inc. | Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US11993657B2 (en) * | 2021-03-16 | 2024-05-28 | Jn Biosciences Llc | Bifunctional molecules for treatment of immune disorders |
| JP2024543164A (ja) * | 2021-11-26 | 2024-11-19 | イミュネクサス・セラピューティクス・リミテッド | 細胞表面上の結合ドメイン分子 |
| CN115078718B (zh) * | 2022-07-22 | 2024-11-12 | 福建师范大学 | 一种基于表面增强拉曼技术检测透明质酸酶的方法 |
| KR20250087648A (ko) * | 2022-11-09 | 2025-06-16 | 리플리겐 코포레이션 | 친화도 제제 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| WO2000060070A1 (en) * | 1999-04-01 | 2000-10-12 | Innogenetics N.V. | A polypeptide structure for use as a scaffold |
| US20100081792A1 (en) * | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| TW200944231A (en) * | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| AU2009298131B2 (en) * | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| WO2010136485A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| EA201190273A1 (ru) * | 2009-05-28 | 2012-12-28 | Глаксо Груп Лимитед | Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз |
| AU2017222700B2 (en) * | 2016-02-26 | 2018-09-27 | Imunexus Therapeutics Limited | Multi-specific molecules |
| JP2024543164A (ja) * | 2021-11-26 | 2024-11-19 | イミュネクサス・セラピューティクス・リミテッド | 細胞表面上の結合ドメイン分子 |
-
2017
- 2017-02-27 AU AU2017222700A patent/AU2017222700B2/en active Active
- 2017-02-27 JP JP2018563747A patent/JP7536424B2/ja active Active
- 2017-02-27 CN CN201780024999.5A patent/CN109310766A/zh active Pending
- 2017-02-27 WO PCT/AU2017/050168 patent/WO2017143406A1/en not_active Ceased
- 2017-02-27 US US16/079,949 patent/US20190338013A1/en not_active Abandoned
- 2017-02-27 EP EP17755659.4A patent/EP3419667A4/en active Pending
- 2017-03-01 TW TW106106646A patent/TW201734037A/zh unknown
-
2019
- 2019-01-02 AU AU2019200005A patent/AU2019200005A1/en not_active Abandoned
-
2020
- 2020-06-22 US US16/946,451 patent/US20210040177A1/en not_active Abandoned
-
2021
- 2021-04-06 US US17/223,935 patent/US11345736B2/en active Active
-
2022
- 2022-05-11 JP JP2022078237A patent/JP2022105574A/ja active Pending
-
2023
- 2023-08-28 US US18/239,052 patent/US20240182542A1/en active Pending
- 2023-12-26 JP JP2023219531A patent/JP7857274B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536322A5 (enExample) | ||
| JP2022512653A5 (enExample) | ||
| AR127371A2 (es) | Receptores quiméricos de flt3 y métodos para usarlos | |
| JP2020519643A5 (enExample) | ||
| JP2017184723A5 (enExample) | ||
| JP2019515646A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| JP2021531826A5 (enExample) | ||
| FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
| JP2018172439A5 (enExample) | ||
| HK1207575A1 (en) | Bispecific asymmetric heterodimers comprising anti-cd3 constructs | |
| PE20220495A1 (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3 | |
| JP2015146822A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2016053091A5 (enExample) | ||
| JP2018537415A5 (enExample) | ||
| PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
| AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2017176174A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| HRP20220131T1 (hr) | Nova terapija s t-staničnim receptorima i imunološka terapija koja koristi iste | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 |